Business Context and Reporting Period
This Form 8-K filing by Lion Biotechnologies, Inc. (not IOVANCE Biotherapeutics, Inc.) reports on events occurring on June 6, 2016, with the report dated June 8, 2016. The filing details the closing of a private placement of equity securities and related corporate governance changes.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital raise:
- Private Placement Price: $4.75 per share.
- Common Stock Issued: 9,684,000 shares.
- Series B Preferred Stock Issued: 11,368,633 shares (stated value $4.75 per share).
- Authorized Series B Preferred Stock: 11,500,000 shares.
- Placement Agents: Jefferies LLC and Piper Jaffray & Co. (fees and expenses paid, specific amounts not disclosed).
Material Changes Versus Prior Period
The filing reports significant structural and capital changes rather than operational performance changes:
- Capital Structure: Issuance of new common stock and Series B Preferred Stock. The common stock issued represented less than 20% of outstanding shares prior to closing.
- Board Composition: The board size increased from five to seven directors. Wayne P. Rothbaum was appointed as a director and Interim Chairman.
- Corporate Governance: A "lock-up" agreement was established preventing officers and directors from selling shares for 60 days and the company from selling shares for 90 days post-agreement.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company intends to solicit stockholder approval for the conversion feature of the Series B Preferred Stock at a future meeting. If approved, the preferred stock will be convertible into common stock at $4.75 per share, subject to beneficial ownership limitations (4.99% cap, adjustable to 9.99% with notice).
Risks and Contingencies:
- Registration Rights Penalty: If the company fails to file or have declared effective registration statements for the resale of securities within prescribed timeframes (30 days to file, 90 days to effectiveness), it must pay investors 1% of the aggregate investment amount for each 30-day period of delay.
- Conversion Uncertainty: If stockholders do not approve the conversion feature, the Series B Preferred Stock will remain non-convertible.
- Investor Control: During the "effective period" (until June 30, 2017 or until Quogue Capital owns less than 5%), the company cannot change board size or amend articles of incorporation without Quogue's consent.
Important Facts for Investor Verification
- Verify the total gross proceeds raised by calculating the sum of common and preferred shares issued at $4.75 per share.
- Confirm the date and outcome of the stockholder meeting required to approve the Series B Preferred Stock conversion feature.
- Monitor the filing status of the registration statements required under the Registration Rights Agreement to avoid the 1% penalty clause.
- Review the specific terms of the Series B Preferred Stock in the Certificate of Designation (Exhibit 3.1) regarding dividend rights and liquidation preferences.
- Note that the company name in the filing is Lion Biotechnologies, Inc., distinct from the metadata provided.